Compare Adaptive Biotechnologies Corp (ADPT) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Veritone Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Veritone Inc trades at $1.5 (market cap $138.04M). The key difference: Adaptive Biotechnologies Corp is far larger — about 29.3× Veritone Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | VERI | |
|---|---|---|
Market Cap | $4.04B | $138.04M |
Sector | Health | Technology |
52-Week High | $25.45 | $8.39 |
52-Week Low | $12.30 | $1.00 |
Enterprise Value | $4.10B | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Veritone (VERI) trades at $1.46, up 1.39% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative profit margins and ROE. Recent news highlights partnerships in AI solutions, but a securities class action lawsuit deadline passed in July 2026.
Outlook remains challenged by persistent losses and high cash burn, offset by analyst optimism with 46% buy ratings. Key risks include the class action, profitability timeline, and competitive AI market. The stock's low price near support levels suggests high volatility potential amid mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
